"Nevirapine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
| Descriptor ID |
D019829
|
| MeSH Number(s) |
D03.383.725.506
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Nevirapine".
Below are MeSH descriptors whose meaning is more specific than "Nevirapine".
This graph shows the total number of publications written about "Nevirapine" by people in this website by year, and whether "Nevirapine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Nevirapine" by people in Profiles.
-
Jao J, Sun S, Bonner LB, Legbedze J, Mmasa KN, Makhema J, Mmalane M, Kgole S, Masasa G, Moyo S, Gerschenson M, Mohammed T, Abrams EJ, Kurland IJ, Geffner ME, Powis KM. Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana. J Infect Dis. 2022 11 28; 226(11):2002-2009.
-
Phanuphak N, Ananworanich J, Teeratakulpisarn N, Jadwattanakul T, Kerr SJ, Chomchey N, Hongchookiat P, Mathajittiphun P, Pinyakorn S, Rungrojrat P, Praihirunyakit P, Gerschenson M, Phanuphak P, Valcour V, Kim JH, Shikuma C. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther. 2012; 17(8):1521-31.
-
Amoroso A, Etienne-Mesubi M, Edozien A, Ojoo S, Sheneberger R, Obiefune M, Hossain MB, Stafford K, Redfield RR. Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):314-20.
-
Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM. Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. Clin Infect Dis. 2010 Mar 01; 50(5):787-91.
-
Jordan WC, Jefferson R, Yemofio F, Tolbert L, Conlon V, Carroll H, Green DC, Green A, Green R. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. J Natl Med Assoc. 2003 Dec; 95(12):1152-7.